U.S. Construction Stock News

Omeros (OMER) just cleared a major hurdle, securing FDA approval for Yartemlea, the first approved therapy for transplant associated thrombotic microangiopathy. This approval shifts the company from a pure development story to an upcoming commercial launch. See our latest analysis for Omeros. The FDA green light has clearly reset expectations, with a 1 day share price return of 75.54 percent and a 90 day share price return of 250.68 percent pushing Omeros to 15.36 dollars. Its 3 year total...

Core Scientific (CORZ) is back in the spotlight after a fresh wave of upgrades from Citizens, with analysts highlighting its high performance computing power pipeline story and upcoming earnings as key catalysts. See our latest analysis for Core Scientific. Those bullish calls come after a volatile stretch, with the share price sitting at $15.57 and showing a 7 day share price return of 14.74 percent but a softer 90 day share price return of minus 7.54 percent. At the same time, the 1 year...

In the past week, Marsh & McLennan reported third-quarter results showing 11.5% year-on-year revenue growth, with non-GAAP earnings per share coming in above analyst expectations and adjusted operating income rising at a double-digit rate. The company is also leaning into growing sustainability and climate disclosure demands, offering ISSB-focused advisory and risk services that align with its broader risk, insurance, and consulting capabilities. We’ll now examine how Marsh & McLennan’s...

Estée Lauder Companies (EL) is back in the spotlight as new CEO Stéphane de La Faverie rolls out the Beauty Reimagined transformation, a shift from damage control to a structured push for growth and profitability. See our latest analysis for Estée Lauder Companies. The stock market seems to be warming back up to that story, with a roughly 45 percent year to date share price return and a three year total shareholder return still deeply negative, suggesting momentum is rebuilding from a...

In December 2025, HEICO reported strong fourth-quarter and full-year 2025 results, with sales rising to US$1,209.41 million for the quarter and US$4.49 billion for the year, alongside higher earnings, a 95th consecutive semiannual dividend of US$0.12 per share, and confirmation of active acquisition spending and a robust deal pipeline. Management signaled that disciplined, earnings-accretive acquisitions remain central to HEICO’s long-term plan, suggesting its recent US$629.8 million of deal...

Wondering if RTX is still worth buying after its huge run up, or if the easy money has already been made? In this article, we break down what the current price might really be telling you about potential future returns. RTX has climbed 5.2% over the last week, 7.6% over the past month, and 60.7% year to date, capping off a 62.5% gain over 1 year and a gain that has nearly tripled investors’ money over 3 years. Those kinds of moves naturally raise the question of whether the stock is now...

In recent days, Fox Corporation drew fresh attention from Wall Street as several major research firms reaffirmed positive views following stronger-than-expected fiscal first-quarter earnings. This cluster of upbeat analyst opinions, building on Fox’s consistent earnings outperformance, highlights how financial execution can meaningfully shift sentiment around a legacy media business. We’ll now explore how Fox’s latest earnings beat and the wave of positive analyst commentary could reshape...

Mattel (MAT) has been drifting in a tight range lately, even as the stock is up over the past 3 months. That makes this a good moment to revisit what the current price implies. See our latest analysis for Mattel. With the share price now at $19.97 and a solid 90 day share price return of 19.87 percent, Mattel’s momentum looks to be rebuilding even though the 1 year total shareholder return of 11.32 percent is more modest. If this kind of steady recovery appeals to you, it could be a good time...

Illumina (ILMN) just gave investors a fresh talking point with its new collaboration and investment in MyOme, a move that pushed the stock up as the market reassessed its growth runway. See our latest analysis for Illumina. The MyOme deal fits a broader shift in sentiment, with Illumina’s recent collaboration driven gains adding to a strong 90 day share price return of 46.78 percent, even as the five year total shareholder return remains deeply negative and suggests investors are only...

First Financial Bancorp (FFBC) has quietly outperformed over the past month, even as its year to date and 1 year returns lag. That mix often signals a market reassessment in progress. See our latest analysis for First Financial Bancorp. With the share price now at $25.8 and a solid 30 day share price return of 6.17 percent, recent strength contrasts with a modestly negative year to date performance. At the same time, a 5 year total shareholder return above 80 percent suggests the longer term...

Concentrix (CNXC) just rolled out a new suite of emotionally aware conversational AI agents, and that launch is quickly becoming the lens investors are using to reassess the stock’s long term potential. See our latest analysis for Concentrix. The launch has arrived at a moment when sentiment is trying to turn, with a 1 month share price return of 16.65 percent helping to offset a weaker 1 year total shareholder return of 3.93 percent and far steeper 3 year losses. The key question now is...

Recent performance and what it might signal American Homes 4 Rent (AMH) has been drifting lower this year, with the stock down about 13% year to date and roughly 11% over the past year despite steady revenue growth. See our latest analysis for American Homes 4 Rent. At around $31.83 per share, American Homes 4 Rent has seen its 1 year share price return move lower even as its 3 year total shareholder return remains solid. This suggests that momentum has cooled while the longer term rental...

In recent days, EyePoint Pharmaceuticals has seen analyst earnings estimates revised upward and received a strong Momentum Style Score of A, alongside a Zacks Rank of #2, reflecting improving expectations for its financial outlook. This shift in sentiment highlights how changes in forecast profitability and momentum indicators can rapidly alter how investors view a clinical-stage eye-disease specialist like EyePoint. We’ll now examine how these upgraded earnings expectations may influence...

Viking Holdings (VIK) is deepening its cultural footprint at Highclere Castle, backing a sustainably designed, permanent events pavilion that replaces the seasonal marquee and extends exclusive Downton Abbey themed experiences for its guests. See our latest analysis for Viking Holdings. That strategy seems to be resonating with investors, with a 30 day share price return of 14.23 percent and a powerful year to date share price return of 66.22 percent signaling building momentum from the...

In recent commentary, RBC Bearings was highlighted for its industrials strength, posting annual revenue growth of 21% over the past five years and earnings per share growth of 19.7%, both ahead of sector peers. Analysts also emphasized the company’s 15.6% free cash flow margin, underscoring its capacity to reinvest in the business or return capital while sustaining performance. We’ll now examine how this strong revenue and earnings trajectory could influence RBC Bearings’ existing...

Knight-Swift Transportation’s recent update showed that its annualized revenue growth over the past two years slowed to 3.7%, while free cash flow margins and return on invested capital have both compressed compared with five years ago. Together, the weaker growth and profitability metrics hint that Knight-Swift may be working through a tougher investment cycle, with fewer high-return projects and less cash available to deploy than in prior periods. Next, we’ll examine how slowing revenue...

McCormick & Company has scheduled a conference call and webcast for its fourth-quarter 2025 financial results on January 22, 2026, to be led by its top executives and supported by detailed presentation materials on the company’s website. This upcoming announcement takes on added weight because analysts are projecting double-digit earnings growth after a year in which McCormick beat third-quarter expectations yet still reduced its full-year 2025 adjusted EPS outlook amid rising costs. We’ll...

In recent months, Five Below reported strong third-quarter results with double-digit comparable sales growth, adjusted its pricing and assortment to focus more tightly on core teen and tween shoppers, and outlined plans to release holiday sales figures alongside a management fireside chat at the 2026 ICR Conference. These moves highlight how Five Below is using selective price increases, product curation, and public commentary to address tariff-related cost pressures while reinforcing its...

Earlier this month, Marriott Vacations Worldwide Corporation announced that its Board of Directors raised the quarterly dividend to US$0.80 per share, payable around January 7, 2026, to shareholders of record on December 24, 2025. The higher dividend, alongside the extension of the share repurchase plan through December 31, 2026, underscores management’s focus on returning capital to investors and confidence in the company’s cash generation. Next, we’ll consider how the richer dividend...

In December 2025, RAPT Therapeutics, Inc. was added to both the NASDAQ Biotechnology Index and the S&P Biotechnology Select Industry Index, following recent clinical and financing milestones. This index inclusion underscores how ozureprubart’s progress, combined with a US$250,000,000 equity raise extending cash runway into mid-2028, is sharpening investor focus on RAPT’s pipeline. We’ll now examine how ozureprubart’s Phase 2b food allergy trial clearance shapes RAPT Therapeutics’...

In recent months, Champion Homes, Inc. reported strong second-quarter momentum, with home sales rising 29% year over year and organic sales orders up 14%, while also surpassing cost-saving synergy goals from its Regional Homes acquisition earlier than planned despite hurricane-related disruptions. Separately, Champion’s collaboration with iUnit Communities on energy-efficient Innovation Cottages in Virginia highlights how offsite-built homes can pair affordability with sustainability,...

Acadia Healthcare Company (ACHC) has been grinding lower for months, but its latest move has some investors wondering whether the selling has gone too far given the company’s underlying growth and profits. See our latest analysis for Acadia Healthcare Company. The stock’s 1-year total shareholder return of -62.04 percent and 3-year total shareholder return of -82.47 percent show that sentiment has deteriorated steadily. The steep 90-day share price return of -39.84 percent suggests that...

Automatic Data Processing (ADP) just paired fresh high frequency hiring data showing steady private sector job gains with a new Thatch ICHRA integration inside its RUN payroll platform, a useful combination for gauging both growth and product momentum. See our latest analysis for Automatic Data Processing. These updates come after a choppy stretch for the stock, with a roughly 3.2% 30 day share price return but a weaker year to date share price return of about 10.9% and a 12 month total...

Garmin (GRMN) has been quietly grinding higher, with the stock up about 7% over the past month even as its past 3 months performance stays negative. That gap has investors reassessing its trajectory. See our latest analysis for Garmin. Zooming out, Garmin’s 30 day share price return of 6.55% contrasts with a flat year to date move and a modestly negative 1 year total shareholder return of 1.28%. This suggests that near term momentum is rebuilding after a cooling phase. If this kind of steady...